Valuation: BioNTech SE

Market Cap 19.63B 21.99B 18.01B 16.39B 30.72B 2,082B 31.33B 215B 86.73B 1,099B 82.52B 80.76B 3,470B P/E 2026 *
-13.3x
P/E 2027 * -14.6x
Enterprise Value 8.53B 9.56B 7.83B 7.12B 13.36B 905B 13.62B 93.54B 37.7B 478B 35.87B 35.11B 1,509B EV / Sales 2026 *
4.81x
EV / Sales 2027 * 5.5x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.73%
1 week+0.77%
Current month-0.73%
1 month-9.67%
3 months-3.37%
6 months-10.26%
Current year-8.06%
1 week 85.81
Extreme 85.81
90.32
1 month 85
Extreme 85
100.02
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
374.58
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/9/26 Sell

Chief Executive Officer

-36,209 0.0150%
10/7/26 Sell

Chief Executive Officer

-24,000 0.0099%
10/5/26 Sell

Chief Executive Officer

-72,000 0.0298%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%+0.77%-15.76%-5.36% 21.99B
-2.37%-5.03%+39.49%+62.39% 62.23B
-0.43%-0.38%+9.86%+67.48% 54.92B
-0.49%+1.64%+19.84%+96.35% 55.26B
-3.33%-5.54%+19.39%+35.69% 42.59B
-2.45%-2.59%+16.36%+98.45% 41.08B
-1.64%+2.32%+219.80%+789.69% 40.33B
-0.68%+21.96%+96.03%+80.94% 33.12B
+0.21%+1.05%+14.81%+46.96% 32.61B
-2.90%+17.12%-42.35%+337.07% 23.98B
Average -1.50%+3.92%+37.75%+160.97% 40.81B
Weighted average by Cap. -1.51%+2.64%+41.07%+153.16%

Financials

2026 *2027 *
Net sales 1.78B 1.99B 1.63B 1.48B 2.78B 188B 2.83B 19.46B 7.84B 99.35B 7.46B 7.3B 314B 1.8B 2.01B 1.65B 1.5B 2.81B 191B 2.87B 19.7B 7.94B 101B 7.55B 7.39B 318B
Net income -1.46B -1.63B -1.34B -1.22B -2.28B -155B -2.33B -15.98B -6.44B -81.57B -6.13B -6B -258B -1.28B -1.44B -1.18B -1.07B -2.01B -136B -2.05B -14.05B -5.67B -71.77B -5.39B -5.28B -227B
Net Debt -11.1B -12.43B -10.18B -9.26B -17.37B -1,177B -17.71B -122B -49.03B -621B -46.65B -45.65B -1,962B -9.75B -10.92B -8.95B -8.14B -15.26B -1,034B -15.57B -107B -43.09B -546B -41B -40.12B -1,724B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-11-02 US$87.53 -0.73% 709,983
26-10-30 US$88.17 -1.08% 631,915
26-10-29 US$89.13 +1.30% 692,715
26-10-28 US$87.99 +1.07% 870,559
26-10-27 US$87.06 +0.23% 1,076,779
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
78.15EUR
Average target price
104.42EUR
Spread / Average Target
+33.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE
  1. Stock Market
  2. Stocks
  3. BNTX Stock